ADHD in children: signs, evaluation, and evidence-based support.

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterised by persistent patterns of inattention and/or hyperactivity-impulsivity that are out of proportion to the child’s developmental level and that meaningfully impair function across multiple settings. It affects an estimated 5–8% of school-age children globally, with symptoms typically present before age 12 and in two or more settings (typically home and school). The American Academy of Pediatrics’ 2019 guideline recommends behavioural parent training as first-line treatment for children aged 4–6, and FDA-approved medication combined with behaviour therapy for ages 6 and above. The inattentive presentation, more common in girls, is under-identified globally because it doesn’t disrupt the classroom in obvious ways. ADHD is one of the most treatable developmental conditions of childhood when the plan — behavioural therapy, environmental scaffolding, and, where indicated, medication — matches the child’s specific presentation.

Three presentations, one diagnosis

The DSM-5-TR recognises three presentations of ADHD: predominantly inattentive (the child who can’t sustain attention but isn’t visibly hyperactive), predominantly hyperactive-impulsive (the child who is in motion and impulsive but whose attention to preferred tasks may be intact), and combined (both patterns present). Children — particularly girls — are often under-identified in the inattentive presentation because they are easier to overlook; they don’t disrupt the classroom in the way a hyperactive child does.

Presentation	Predominant symptom pattern	Often missed in	Typical school report
Predominantly inattentive	Difficulty sustaining attention; appears not to listen; loses things; avoids tasks requiring sustained focus	Girls, quiet children, children whose grades sit above the floor	”Bright but inconsistent.” “Daydreams.” “Doesn’t finish work.”
Predominantly hyperactive-impulsive	Constant motion; interrupts; difficulty waiting turn; speaks excessively	Children whose behaviour is read as a discipline issue rather than developmental	”Disruptive.” “Can’t sit still.” “Doesn’t follow rules.”
Combined	Both inattention and hyperactivity-impulsivity present at clinical threshold	Less often missed (both patterns are visible)	Multi-domain concerns; usually flagged early

Where the diagnosis lives

ADHD is a clinical diagnosis based on DSM-5-TR criteria; there is no blood test or brain scan that confirms it. The clinician needs to establish that (1) at least six symptoms of inattention or hyperactivity-impulsivity have been present for six months, (2) symptoms are present in two or more settings (typically home and school), (3) symptoms began before age 12, and (4) symptoms cause meaningful functional impairment. Behavioural rating scales (Vanderbilt, Conners-3) collect parent and teacher data; the clinician triangulates them with developmental history and direct observation.

What the evidence says about treatment

The most influential study in paediatric ADHD treatment is the NIMH-sponsored Multimodal Treatment Study of ADHD (MTA), launched in the 1990s and followed for decades. Its findings, which have shaped clinical guidelines globally, are roughly: (1) carefully managed stimulant medication produces the strongest short-term symptom reduction; (2) high-quality behavioural therapy produces meaningful improvement, particularly in functional outcomes; (3) the combination of medication plus behavioural therapy produces the strongest sustained outcomes for many children, particularly when co-occurring anxiety, learning differences, or family stress are present.

The American Academy of Pediatrics’ 2019 clinical practice guideline reflects this evidence. For children 4 to 6 years old, the AAP recommends parent training in behaviour management as first-line, with medication considered only where behavioural therapy has not produced sufficient improvement. For children 6 to 18, the AAP recommends FDA-approved medications and behaviour therapy, ideally combined, plus school accommodations.

The choice between medication, behavioural intervention, or both is the family’s. Our job is to give you the data clearly, not to push.

What a good plan does

A defensible ADHD plan addresses three things in order. First, sleep, regulation, and the morning routine — a sleep-deprived child looks identical to a child with worse ADHD, and the morning routine is often where the day’s symptoms snowball. Second, the antecedents to difficulty — the five minutes before a meltdown, the three seconds before an impulse — most of which can be redesigned at the parent and environment level. Third, the child’s own toolkit — externalised executive-function scaffolds (visible plans, time estimation, transition rituals) that compensate for the underlying working-memory and time-perception challenges.

Medication, where indicated, is added to the plan when the executive-function load is heavy enough that behavioural strategies alone aren’t closing the gap, when school is at risk, or when self-esteem is starting to erode in measurable ways. The conversation about medication should be informed by the data already collected over the preceding weeks of behavioural intervention — never started cold.